NO20044258L - Cystein proteaseinhibitor - Google Patents

Cystein proteaseinhibitor

Info

Publication number
NO20044258L
NO20044258L NO20044258A NO20044258A NO20044258L NO 20044258 L NO20044258 L NO 20044258L NO 20044258 A NO20044258 A NO 20044258A NO 20044258 A NO20044258 A NO 20044258A NO 20044258 L NO20044258 L NO 20044258L
Authority
NO
Norway
Prior art keywords
protease inhibitor
cysteine protease
cysteine
inhibitor
protease
Prior art date
Application number
NO20044258A
Other languages
English (en)
Norwegian (no)
Inventor
Akio Yamada
Yasushi Kawaguchi
Nobuhiko Katunama
Natsuko Takakura
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Publication of NO20044258L publication Critical patent/NO20044258L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
NO20044258A 2002-11-29 2004-10-07 Cystein proteaseinhibitor NO20044258L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002347801 2002-11-29
JP2003147035 2003-05-23
PCT/JP2003/014263 WO2004050118A1 (ja) 2002-11-29 2003-11-10 システインプロテアーゼ阻害剤

Publications (1)

Publication Number Publication Date
NO20044258L true NO20044258L (no) 2004-10-28

Family

ID=32473655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044258A NO20044258L (no) 2002-11-29 2004-10-07 Cystein proteaseinhibitor

Country Status (8)

Country Link
US (1) US20050148504A1 (ja)
EP (1) EP1568377A1 (ja)
JP (1) JPWO2004050118A1 (ja)
KR (1) KR20050044758A (ja)
AU (1) AU2003277644A1 (ja)
CA (1) CA2481489A1 (ja)
NO (1) NO20044258L (ja)
WO (1) WO2004050118A1 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1503628A4 (en) * 2002-04-29 2006-11-29 First Products Inc FROZEN BAKERY PRODUCTS FOR MICROWAVE OVENS
US20080260926A1 (en) * 2003-04-29 2008-10-23 First Products, Inc. Frozen Microwavable Bakery Products
GB0423352D0 (en) 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
CN101084004A (zh) * 2004-12-22 2007-12-05 帝斯曼知识产权资产管理有限公司 单个酶促步骤中的血压降低寡肽
JP4180645B2 (ja) * 2005-09-30 2008-11-12 森永乳業株式会社 グルカゴン様ペプチド−1分泌促進剤及び食後血糖値上昇抑制剤
JP4536665B2 (ja) * 2006-02-08 2010-09-01 森永乳業株式会社 カゼイン加水分解物含有造粒物の製造方法
CA2646328A1 (en) * 2006-04-20 2007-11-01 First Products, Inc. Frozen microwaveable dough products
EP2030629B1 (en) * 2006-06-09 2014-04-30 Morinaga Milk Industry Co., Ltd. Alpha-s-casein as lipid-metabolism-improving agent
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
JP4956164B2 (ja) * 2006-12-06 2012-06-20 味の素株式会社 メラニン輸送及び/又は放出抑制剤
WO2009124178A1 (en) * 2008-04-02 2009-10-08 Cornell Research Foundation, Inc. Method for prophylaxis or treatment of feline infectious peritonitis
JP5261114B2 (ja) * 2008-09-30 2013-08-14 テルモ株式会社 酸性タイプ液状経腸栄養剤
WO2010066542A1 (en) 2008-12-09 2010-06-17 Unilever Plc Frozen aerated confections and methods for producing them
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
AU2010262763A1 (en) * 2009-06-19 2012-01-19 Oral Health Australia Pty Ltd Casein derived protease inhibitory peptides
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2012070964A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Модифицированные олигопептиды с противораковыми свойствами и способ их получения
WO2012113037A1 (en) * 2011-02-25 2012-08-30 The University Of Melbourne Method for inhibiting proteins
AU2013249522A1 (en) * 2012-04-16 2014-10-30 The Cleveland Clinic Foundation Multivalent breast cancer vaccine
ES2444299B1 (es) * 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
PL2986157T3 (pl) 2013-04-08 2020-07-27 N.V. Nutricia Fermentowana kompozycja odżywcza z inhibitorem proteazy tiolowej
US20160175351A1 (en) * 2013-06-24 2016-06-23 Duke University Cancer treatment
ES2544153B1 (es) * 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20220119496A1 (en) * 2019-02-15 2022-04-21 Andrzej Marek RAPAK Inhibitors of cysteine peptidases isolated from natural raw materials and use of the inhibitors in medicine and veterinary medicine
JP6797966B2 (ja) * 2019-04-24 2020-12-09 森永乳業株式会社 胃内酸性プロテアーゼ酵素活性阻害剤、ラクトフェリン組成物の製造方法、及びラクトフェリン組成物
AU2021264554A1 (en) * 2020-05-01 2023-01-05 Arjil Biotech Holding Company Limited Compounds and methods for prevention and treatment of coronavirus infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3378279B2 (ja) * 1991-11-07 2003-02-17 株式会社日清製粉グループ本社 ペプチドおよびその製造方法
JPH05184382A (ja) * 1992-01-13 1993-07-27 Kyodo Nyugyo Kk 蛋白分解酵素活性疎外物質の製法
JP3344497B2 (ja) * 1993-03-18 2002-11-11 雪印乳業株式会社 新規システインプロテアーゼインヒビター
JP3460851B2 (ja) * 1993-04-28 2003-10-27 雪印乳業株式会社 新規システインプロテアーゼインヒビター
JP3276753B2 (ja) * 1993-11-12 2002-04-22 大鵬薬品工業株式会社 カテプシンl特異的阻害ポリペプチド
JPH07242600A (ja) * 1994-03-02 1995-09-19 Yoshimitsu Nagao チオールプロテアーゼ阻害剤
WO1995032727A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
EP0760673A1 (en) * 1994-05-26 1997-03-12 Abbott Laboratories INHIBITION OF ATTACHMENT OF $i(H. INFLUENZAE) TO HUMAN CELLS
JP3805804B2 (ja) * 1994-09-14 2006-08-09 森永乳業株式会社 動脈硬化防止剤
JPH09221425A (ja) * 1996-02-13 1997-08-26 Taiho Yakuhin Kogyo Kk チオールプロテアーゼ阻害剤
US5914348A (en) * 1996-02-21 1999-06-22 Taiho Pharmaceutical Co., Ltd. Substance FA-70D, process for producing the same, and uses thereof
PE68599A1 (es) * 1997-04-25 1999-09-26 Smithkline Beecham Corp Inhibidores de proteasas
JP3643925B2 (ja) * 1998-08-24 2005-04-27 大鵬薬品工業株式会社 Fa−70c1物質
JP4592127B2 (ja) * 1999-03-30 2010-12-01 雪印乳業株式会社 骨吸収抑制剤
JP2001139534A (ja) * 1999-11-16 2001-05-22 Yoshimitsu Nagao バリン誘導体およびその用途

Also Published As

Publication number Publication date
JPWO2004050118A1 (ja) 2006-03-30
WO2004050118A1 (ja) 2004-06-17
US20050148504A1 (en) 2005-07-07
AU2003277644A1 (en) 2004-06-23
EP1568377A1 (en) 2005-08-31
CA2481489A1 (en) 2004-06-17
KR20050044758A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
NO20044258L (no) Cystein proteaseinhibitor
ATE461200T1 (de) Inhibitoren von cysteinprotease
DK1817276T3 (da) Cathepsin cysteine protease inhibitors
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
EP1499336A4 (en) PROTEASE INHIBITORS
DE60215683D1 (de) Uhrgehäuse
EP1694647A4 (en) INHIBITORS OF CYSTEINE PROTEASES OF THE CATHEPSIN TYPE
DK1466962T3 (da) Alkalisk protease
ITMI20021399A0 (it) Inibitori della cicloossigenasi 2
EP1673336A4 (en) INHIBITORS OF CATHEPSIN AND CYSTEINE PROTEASE
DK1466970T3 (da) Alkalisk protease
AU2003234630A1 (en) Cysteine protease inhibitors
EP1663279A4 (en) MODIFIED PROTEASE INHIBITORS
EP1704142A4 (en) PROTEASE INHIBITORS
DK1347044T3 (da) Alkalisk protease
NO20025786L (no) Protaseinhibitorer
AU2003269984A8 (en) Protease inhibitors
EP1706402A4 (en) INHIBITORS OF CATHEPSINE TYPE PROTEIN CYSTEINES
NO20025005D0 (no) Proteaseinhibitorer
DE60309858D1 (de) Kompressor
DE60309988D1 (de) Kompressor
EP1715920A4 (en) CATHEPSINCYSTEINPROTEASEHEMMER
AU2003263738A8 (en) Protease inhibitors
NO20032328L (no) Proteaseinhibitorer
DE60315020D1 (de) (2s)-2-ethylphenylpropionsäurederivat